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Abstract
Rationale—Occupational exposure to indium compounds, including indium–tin oxide, can result 
in potentially fatal indium lung disease. However, the early effects of exposure on the lungs are 
not well understood.
Objectives—To determine the relationship between short-term occupational exposures to indium 
compounds and the development of early lung abnormalities.
Methods—Among indium–tin oxide production and reclamation facility workers, we measured 
plasma indium, respiratory symptoms, pulmonary function, chest computed tomography, and 
serum biomarkers of lung disease. Relationships between plasma indium concentration and health 
outcome variables were evaluated using restricted cubic spline and linear regression models.
Measurements and Main Results—Eighty-seven (93%) of 94 indium–tin oxide facility 
workers (median tenure, 2 yr; median plasma indium, 1.0 μg/l) participated in the study. 
Spirometric abnormalities were not increased compared with the general population, and few 
subjects had radiographic evidence of alveolar proteinosis (n = 0), fibrosis (n = 2), or emphysema 
(n = 4). However, in internal comparisons, participants with plasma indium concentrations ≥1.0 
μg/l had more dyspnea, lower mean FEV1 and FVC, and higher median serum Krebs von den 
Lungen-6 and surfactant protein-D levels. Spline regression demonstrated nonlinear exposure 
response, with significant differences occurring at plasma indium concentrations as low as 1.0 μg/l 
compared with the reference. Associations between health outcomes and the natural log of plasma 
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indium concentration were evident in linear regression models. Associations were not explained 
by age, smoking status, facility tenure, or prior occupational exposures.
Conclusions—In indium–tin oxide facility workers with short-term, low-level exposure, plasma 
indium concentrations lower than previously reported were associated with lung symptoms, 
decreased spirometric parameters, and increased serum biomarkers of lung disease.
Keywords
occupational lung disease; pulmonary alveolar proteinosis; fibrosis; Krebs von den Lungen-6; 
surfactant protein-D
Indium lung disease is a potentially fatal condition that can occur in workers exposed to 
indium compounds including indium–tin oxide (1). The disease is characterized by 
pulmonary alveolar proteinosis that may progress to fibrosis with or without emphysema 
with relatively short latency (1–13 yr from first exposure to diagnosis) (2). Epidemiologic 
studies of indium–tin oxide production facilities where indium lung disease cases occurred 
have demonstrated subclinical disease in coworkers (3–7). In one indium–tin oxide 
workplace, high-resolution computed tomography (HRCT) of the chest showed interstitial 
changes in 21% of workers and emphysematous changes in 13% (3). A multisite study in 
Japan found increases in nonspecific serum biomarkers of lung damage, including Krebs 
von den Lungen (KL)-6 and surfactant protein (SP)-D associated with increases in serum 
indium levels; the authors recommended keeping serum indium, which appeared to be a 
marker of cumulative exposure, below 3 μg/l to prevent lung disease (5).
We previously reported two cases of pulmonary alveolar proteinosis, including one fatality, 
among workers at a United States indium–tin oxide production and reclamation facility (8). 
Indium compounds encountered at the facility included indium metal, indium salts, indium 
oxide, and indium–tin oxide. Review of corporate medical surveillance data demonstrated a 
4-fold excess of spirometric restriction after hire and greater than expected declines in FEV1 
on serial examination (7). After-hire diffusing capacity defects were common. Significant 
associations between lung function abnormalities and blood indium concentration were not 
seen, but lung function test quality was inconsistent, and an insensitive blood indium 
analytical method with a detection limit of 5 μg/l had been used. Although more recently 
hired workers had fewer abnormalities, the available data suggested that additional efforts to 
reduce exposures and prevent adverse health effects were needed.
The facility introduced a variety of engineering controls and expanded respiratory 
protection. To inform further preventive interventions, we sought to better understand the 
relationship between respiratory health and exposure to indium compounds in the current 
workforce. Our primary question was: Are current exposures in the facility low enough to 
prevent lung damage? To answer this question, we focused on current workers whose 
experience would best reflect recent conditions. Given our previous observations, we chose 
to use spirometry and diffusing capacity tests, although they appeared to be of limited utility 
in other workplaces (3–5). For serum biomarkers, KL-6 and SP-D, as well as general 
markers of inflammation, were included. In addition, we explored the potential roles of 
YKL-40, a chitinase-like protein produced by macrophages that was recently reported to be 
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a predictor of disease progression in pulmonary alveolar proteinosis unrelated to indium (9), 
and granulocyte-macrophage colony-stimulating factor (GM-CSF) auto-antibodies, which 
have been demonstrated to mediate the pathogenesis of idiopathic pulmonary alveolar 
proteinosis (10). GM-CSF autoantibodies had been detected in one of the present facility's 
cases of pulmonary alveolar proteinosis, raising the possibility of an exposure-related 
autoimmune response (8). HRCT of the chest was used because of its greater sensitivity for 
subclinical changes in indium–tin oxide workers compared with plain chest radiography (3). 
Finally, we recognized the need to use an analytical method for indium comparable in 




The Institutional Review Board of the National Institute for Occupational Safety and Health 
(NIOSH) approved this study. All individuals employed at an indium–tin oxide production 
facility when this cross-sectional study was initiated (July 16, 2012) were invited to give 
written informed consent for an interviewer-administered questionnaire (available in the 
online supplement), spirometry, measurement of diffusing capacity, HRCT scan of the chest, 
and blood draw. The questionnaire addressed respiratory symptoms and diagnoses, smoking 
history, work history, and demographic information. The respiratory questions were adapted 
from validated survey instruments (11–13). We used job title and department to classify 
participants into the following department categories: production (including indium oxide 
production, indium–tin oxide production, grinding, reclaim, and research and development), 
production support (e.g., maintenance, shipping/receiving, engineer, and janitorial), 
laboratory, and office.
Pulmonary Function Tests
Standard spirometry and diffusing capacity testing was performed and interpreted according 
to published guidelines (14–18). We conducted spirometry testing using a dry rolling-seal 
spirometer (14). Test results were interpreted using reference values generated from the 
Third National Health and Nutrition Examination Survey (15, 16). We defined obstruction 
as FEV1 and ratio of FEV1 to FVC below their respective lower limits of normal (fifth 
percentiles) with a normal FVC. We defined restrictive pattern as a normal FEV1/FVC ratio 
with FVC below the lower limit of normal. We classified participants with both FEV1/FVC 
ratio and FVC below the lower limit of normal as having mixed obstructive and restrictive 
abnormalities. Participants were considered to have any spirometric abnormality if they met 
the definition of obstruction, restrictive pattern, or mixed pattern.
We measured the diffusing capacity of the lung for carbon monoxide (DLCO) using the single 
breath technique with helium as the tracer gas (17). Test results were interpreted using 
reference values generated from a stratified random sample of a state population (18). For 
alveolar volume (VA), we adjusted the predicted values by a factor of 0.88 for Black and 
Asian participants. We defined low DLCO and VA on the basis of their respective lower 
limits of normal.
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Chest HRCT scans were offered to all nonpregnant participants and were conducted at a 
local radiology center using a low-dose (∼1 mSv per scan), noncontiguous protocol. One 
participant declined HRCT but provided digital images from a chest CT done 3 months 
before the survey; we accepted these images for our analyses. All scans were systematically 
reviewed by a thoracic radiologist according to an international classification scheme (19), 
with attention to changes described in workers with indium lung disease (i.e., pulmonary 
alveolar proteinosis, fibrosis, and emphysema).
Plasma Metal and Serum Biomarker Analyses
We collected blood for measurement of metal concentrations and biomarkers of 
inflammation and interstitial lung disease. Ten milliliters of blood were collected using trace 
metal–free evacuated containers and processed to isolate plasma. Another 10 ml of blood 
were collected using serum-separator evacuated containers and processed to isolate serum. 
Samples were stored frozen at −80°C until analysis.
Plasma samples were analyzed by a commercial laboratory for indium and tin using 
inductively coupled plasma mass spectrometry assays. The indium analytical method had a 
limit of detection of 0.03 μg/l and a limit of quantification of 0.1 μg/l. The tin method had a 
limit of detection of 2.0 μg/l.
The serum concentrations of C-reactive protein (CRP), YKL-40, KL-6, and SP-D were 
measured using ELISA kits (R&D Systems, Minneapolis, MN). GM-CSF autoantibodies 
were measured by ELISA as described previously (20), and lactate dehydrogenase (LDH) 
was measured by colorimetric assay (R&D Systems). Reference values for CRP, LDH, 
KL-6, and YKL-40 were determined from serum samples from 30 healthy individuals (15 
male and 15 female subjects). Reference values for SP-D and GM-CSF autoantibodies were 
determined from serum samples from 101 healthy individuals (44 male and 57 female 
subjects). The upper limits used to define a test result as abnormally elevated were as 
follows: CRP, 14,365.5 ng/ml; LDH, 101.8 IU/ml; YKL-40, 109.8 ng/ml; KL-6, 466.7 
U/ml; SP-D, 375.2 ng/ml; GM-CSF autoantibodies, 3.0 μg/l.
Statistical Analyses
Numeric data were evaluated for normality by the Shapiro-Wilk test, summarized using 
descriptive statistics, and presented as mean ± SEM if normally distributed and as median 
(interquartile range [IQR]) if nonnormally distributed. Plasma indium was the primary 
exposure metric. Results below the limit of detection, which were few, were assigned a 
value of 0.015 μg/l (half of the limit of detection). For results falling between the limit of 
detection and the limit of quantification, we used the measured value.
Standardized morbidity ratios (SMRs) of symptoms, diagnoses, and lung function 
abnormalities were calculated using data obtained from the United States adult population 
adjusted for race/ethnicity (white, black, Hispanic), sex, age, and smoking status (13). For 
spirometric restriction, we also examined the effect of body mass index.
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Relationships between exposure and health outcomes were evaluated after stratifying by 
plasma indium concentration on the basis of the median and tertile values. Normally 
distributed data were evaluated for equal variance by the O'Brien test and analyzed by 
Student's t test (for two groups) or ANOVA (for more than two groups). Nonnormally 
distributed data were analyzed by the Mann-Whitney U test (for two groups) or by the 
Kruskal-Wallis test (for more than two groups). For categorical data, χ2 test or Fisher's exact 
test were used. Recursive partitioning also was used to create plasma indium categories that 
achieve the maximum association between plasma indium and the health outcome of 
interest.
Logistic regression was used to assess the relationship between plasma indium (categorized 
by the median value) and dichotomous health outcomes. Spline and linear regression models 
were used to assess the relationship between plasma indium (or the natural log of plasma 
indium) and continuous health outcomes. For the spline regression models, we developed 
restricted cubic splines using a published SAS macro (21). Restricted cubic splines are a 
type of spline regression in which polynomials are defined over adjacent intervals and joined 
together at a small number of “knots.” We specified five knots and modeled the difference 
between the value of the health outcome for any given plasma indium concentration and the 
value of the health outcome for a reference plasma indium concentration. We set the 
reference plasma indium concentration at half of the limit of detection because it was the 
lowest value assigned to any participant.
Final adjusted models included the following covariates: cigarette smoking status (current/
former/never), facility tenure (years), and age (years). Age was not included as a covariate in 
models of percent predicted values of lung function parameters because the percent 
predicted values account for age. The effect of prior occupational exposures was also 
examined.
Analyses were conducted using SAS software version 9.3 and JMP software version 10.0.1 
(SAS Institute, Inc., Cary, NC). All P values reported are two-sided. We considered P ≤ 
0.05 to be significant.
Results
Participant Health Outcome Variables
Eighty-seven (93%) of 94 eligible indium–tin oxide facility employees participated in the 
study (Table 1). Median facility tenure was short (2 yr), and approximately half of the 
participants worked in production. Nineteen (22%) of the 87 participants were included in 
the previous review of corporate medical surveillance records (7). All 87 participants 
completed the questionnaire, and most underwent lung function testing (n = 75; 86%), serum 
biomarker analysis (n = 80; 92%), and a chest HRCT scan (n = 70; 80%).
The majority (56%) of participants were asymptomatic; 6 to 22% reported a chest symptom 
or a prior or current diagnosis of asthma (Table 2). Most (n = 14; 74%) asthma diagnoses 
were made before employment at the facility. Two participants reported a diagnosis of lung 
scarring or fibrosis; none reported a current diagnosis of chronic obstructive lung disease. 
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Few participants had an abnormality of spirometry or gas diffusion (Table 2). There were no 
associations between spirometric or diffusing capacity abnormalities and smoking status, but 
the FEV1% and FEV1/FVC ratio were significantly lower in current smokers (not shown). In 
adjusted comparisons with the United States adult population, participants had significantly 
higher-than-expected prevalence of wheeze in the last 12 months (SMR 1.6; 95% confidence 
interval [CI], 1.0–2.5), lifetime asthma diagnosis (SMR, 3.2; 95% CI, 2.1–5.1), and current 
asthma diagnosis (SMR, 2.7; 95% CI, 1.4–5.2). Other symptoms and spirometric 
abnormalities were not in excess.
Of the 70 participants who had a chest HRCT, none had radiologic evidence of pulmonary 
alveolar proteinosis, two had evidence of early fibrosis, and four others had evidence of 
emphysema (centrilobular in one and paraseptal in three). The signs of emphysema occurred 
in current smokers between 26 and 42 years of age, with 6 to 29 pack-year smoking 
histories. Most (n = 5) of these radiographic abnormalities occurred in participants who 
reported prior exposure to asbestos, silica, or other lung hazards (P = 0.3971).
Of the 80 participants who provided blood samples for biomarker analysis, KL-6 was 
elevated in 46 (58%), YLK-40 in 15 (19%), SP-D in 8 (10%), and CRP in 2 (3%). None had 
elevation of LDH or GM-CSF autoantibodies. Median KL-6 and SP-D were significantly 
lower in current smokers than in other participants (not shown).
Plasma Indium and Tin
Indium was detected in nearly all of the 80 participants evaluated (n = 76; 95%), and 
concentrations were quantifiable in most of the participants (n = 70; 88%). Fourteen (18%) 
had plasma indium concentrations ≥ 3 μg/l, with a maximum value of 37 μg/l. The median 
plasma indium concentration was 1.0 μg/l (Table 3). The median plasma indium 
concentration was higher in participants with tenure of ≥ 2 years compared with <2 years 
(Table 3). The median plasma indium concentration also varied by job category (Table 3).
Only two participants had quantifiable concentrations of tin in plasma.
Relationship between Plasma Indium and Health Outcomes
Stratification by the median plasma indium concentration of 1 μg/l demonstrated multiple 
associations between plasma indium and health outcomes (Table 2). Participants in the 
higher plasma indium group had a higher prevalence of dyspnea, wheeze in the absence of 
an upper respiratory infection, and lifetime asthma diagnosis (Table 2). These associations 
remained evident in logistic regression models adjusted for smoking status (not shown). In 
particular, dyspnea remained associated with plasma indium concentration ≥ 1 μg/l in a 
model adjusted for age, smoking status, facility tenure, and prior exposure to asbestos, silica, 
or other lung hazards (odds ratio, 5.3; 95% CI, 1.2–30.5; P = 0.0267).
The mean FEV1% and mean FVC% were lower in the higher plasma indium group (Table 
2). Although the prevalence of specific spirometric abnormalities did not differ, the 
prevalence of any spirometric abnormality was increased in the higher plasma indium group 
(Table 2). Although similar trends in means and prevalence of abnormalities were observed 
for the gas diffusion parameters, the differences were not significant (Table 2). Chest HRCT 
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abnormalities consistent with indium lung disease did not differ by plasma indium group 
(not shown). None of the health outcomes associated with plasma indium in these 
unadjusted analyses was associated with prior exposure to asbestos, silica, or other lung 
hazards (not shown).
The median serum KL-6 and median serum SP-D were higher in the higher plasma indium 
group (Table 2). Furthermore, the prevalence of participants with an elevated KL-6 was 
higher in the higher plasma indium group (75% vs. 40%; P = 0.001). In contrast, the 
difference in prevalence of participants with an elevated SP-D (15% vs. 5%) was not 
significant.
Stratification by tertile of plasma indium concentration (i.e., <0.5, 0.5 to <1.6, ≥1.6 μg/l) 
also demonstrated increases in adverse health outcomes with increasing plasma indium 
concentration (not shown). Significant differences were observed for FEV1% and KL-6. 
Mean FEV1% was 104 ± 1.9 for the lowest tertile, 93 ± 3.5 for the middle tertile, and 93 ± 
2.6 for the highest tertile (P = 0.001). Median KL-6 (U/ml) was 406 (IQR, 303–606) for the 
lowest tertile, 493 (IQR, 370–577) for the middle tertile, and 818 (IQR, 609–1,360) for the 
highest tertile (P < 0.0001). These observations were consistent with the outcomes of 
recursive partitioning, which identified plasma indium concentrations of 0.5 μg/l for FEV1% 
(indium <0.5 μg/l: n = 24, mean = 103.9; indium ≥0.5 μg/l: n = 51, mean = 93.0) and 2.1 
μg/l for KL-6 (U/ml) (indium <2.1 μg/l: n = 58, mean = 464; indium ≥2.1 μg/l: n = 22, mean 
= 1,115) as cutoffs for maximal association between plasma indium concentration and these 
health outcomes.
Adjusted restricted cubic splines for FEV1%, FVC%, KL-6, and SP-D by plasma indium 
concentration showed nonlinear relationships (Figure 1) and demonstrated that the estimated 
FEV1% and FVC% were lower and the estimated KL-6 and SP-D were higher than the 
corresponding values for the reference plasma indium concentration of 0.015 μg/l. 
Significant differences were seen for FEV1% starting at a plasma indium concentration of 
1.0 μg/l, for FVC% and KL-6 at 1.5 μg/l, and for SP-D at 7.0 μg/l (Table 4).
In unadjusted linear regression models, FEV1% and FVC% were not associated with plasma 
indium concentration (not shown) but were associated with the natural log of plasma indium 
concentration (Table 5). KL-6 and SP-D were associated with both plasma indium 
concentration (not shown) and the natural log of plasma indium concentration (Table 5). 
Including smoking status, facility tenure, and age as covariates had little effect on the 
coefficients for the indium variable or the significance of the models (Table 5). In addition, 
including prior exposure to asbestos, silica, or other lung hazards as a covariate in the 
models had little effect (not shown).
Discussion
In an indium–tin oxide production and reclamation workforce with a median tenure of 2 
years, median plasma indium concentration below the current Japanese standard of 3.0 μg/l 
(22), and few radiographic abnormalities on chest HRCT, we found consistent associations 
between plasma indium concentration and clinical, functional, and laboratory biomarkers. 
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Higher plasma indium concentrations were associated with more dyspnea, reduced lung 
function, and increased serum KL-6 and SP-D concentrations. These differences were not 
explained by age, smoking status, length of employment at the facility, or prior occupational 
exposures and were observed at lower plasma indium concentrations than previously 
reported (5). On the basis of these findings, we recommend efforts to further reduce 
exposure to indium compounds in this industry and the use of medical surveillance in at-risk 
workforces, which includes, at a minimum, a sensitive plasma indium test and high quality 
spirometry.
Our results indicate that spirometry is a sensitive measure of the early adverse effects of 
indium exposure on the lungs. Although specific spirometric abnormalities were not 
increased for the entire group compared with national rates, participants with higher plasma 
indium concentrations had a higher prevalence of any spirometric abnormality than 
participants with lower plasma indium concentrations. A restrictive pattern was the most 
common abnormality, which is consistent with prior reports (2, 7). Furthermore, results for 
FEV1% and FVC% suggest that indium compound exposures corresponding to plasma 
indium concentrations as low as 0.5 μg/l are associated with adverse effects on lung 
function. Restricted cubic spline analyses revealed a maximum effect at a plasma indium 
concentration of only 1.5 μg/l, a value at which FEV1% and FVC% were 18 and 11 
percentage points lower, respectively, than corresponding reference values. Our results 
differ from previous reports that either did not identify any relationship between serum 
indium concentration and spirometric parameters or only identified differences at high 
serum indium concentrations (≥20 μg/l) (3–5). One explanation is that our approach 
extended beyond simple linear analysis and included spline regression and log 
transformation of the exposure metric, which were important in detecting the associations. 
High-quality spirometric measurements and the use of robust reference equations may also 
have contributed (15, 16). It is also possible that the exposure–response relationship varies 
by plasma indium concentration and is steeper at the lower end of exposure.
The serum biomarkers KL-6 and SP-D appear to be sensitive indicators of early adverse 
effects of indium compound exposure on the lungs. KL-6 was elevated in >50% of 
participants and SP-D was elevated in 10%, and both biomarkers were positively associated 
with plasma indium concentration. Results for KL-6 were particularly striking: participants 
in the highest tertile of plasma indium (≥1.6 μg/ l) had a median KL-6 more than double that 
of participants in the lowest tertile of plasma indium (<0.5 μg/l), and significant effects were 
noted with spline regression at a plasma indium concentration of 1.5 μg/l. SP-D appeared 
less sensitive than spirometric parameters and KL-6, with significant effects noted with 
spline regression at a plasma indium concentration of 7.0 μg/l. Although other explanations 
are possible, the associations between plasma indium and these biomarkers of lung disease 
are likely to reflect the effect of exposure to indium compounds. These associations have 
been observed consistently in indium-exposed workforces globally (5, 6, 23), and a recently 
reported 5-year follow-up of indium workers found that serum indium, KL-6, and SP-D 
declined to similar degrees with cessation or reduction of exposure (24).
In contrast, LDH and CRP, two widely used clinical laboratory tests, were rarely elevated 
and were not associated with plasma indium concentration. YKL-40 was elevated in nearly 
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20% of participants, but levels were not associated with plasma indium concentration. GM-
CSF autoantibody concentration was not increased in any participant and was not associated 
with plasma indium concentration. If indium compound exposure can provoke an anti–GM-
CSF autoimmune response, as suggested previously (8, 25), these results do not support the 
monitoring of serum GM-CSF autoantibody levels in at-risk individuals in the absence of 
signs or symptoms of pulmonary alveolar proteinosis.
The excesses of wheeze and asthma and their association with plasma indium concentration 
were unanticipated. Because asthma is a common diagnosis, it is possible that some indium–
tin oxide workers with indium compound exposure–related respiratory symptoms were 
misdiagnosed with asthma. However, most asthma diagnoses preceded employment. Further 
evaluation of these associations using diagnostic tests for asthma may be useful.
The prevalence of restrictive spirometry in this study (11%) was lower than that found at the 
same facility in a previous report (31%), in which half of the participants had plasma indium 
concentrations ≥ 5 μg/l, one participant was a sentinel case, and most participants were no 
longer employed at the facility at the time of the current study (7, 8). This difference could 
be related to exposure reduction within the facility over time or to the introduction of new 
hires and/or the inclusion of nonproduction workers in the current study. Indeed, nearly 80% 
of the participants in the current study were not included in the previous evaluation. Half of 
the participants in our 2012 study had been hired in the preceding 2 years and 75% had been 
hired in the preceding 5 years, so few of the participants had worked at the facility when the 
cases of pulmonary alveolar proteinosis occurred (1999–2005) or when high rates of 
restrictive spirometry were documented (2002–2010). Systematic longitudinal exposure 
assessment is lacking, but the intervening introduction of engineering controls (e.g., machine 
enclosures, isolation of some dusty processes, and expanded use of task-based respiratory 
protection) likely reduced exposures for these more recently hired workers. We chose to 
include nonproduction workers (e.g., accountants, human resources specialists, customer 
service coordinators, and managers) due to concerns that they may have had unappreciated 
exposures. Four of these participants had plasma indium concentrations above the limit of 
quantification, confirming that even some office-based participants were exposed to indium 
compounds. Nonetheless, their inclusion contributed to expanding the range of exposures 
experienced by the study participants and to enabling the evaluation of an exposure–
response relationship.
Associations between interstitial or emphysematous abnormalities on HRCT and plasma 
indium concentration have been previously reported (3, 5). The lack of such associations in 
the present study may be because these abnormalities were uncommon among participants. 
In addition, not all participants underwent HRCT, which may have hindered our ability to 
detect associations between plasma indium concentration and radiographic abnormalities. 
Nonetheless, the relatively young ages (26–42 yr) and limited smoking histories (6–29 pack-
yr) of the participants with emphysema on HRCT make it difficult to attribute these 
abnormalities solely to smoking.
The lack of association between diffusing capacity and plasma indium concentration was 
also unexpected and differs from a prior report in which DLCO was reduced in participants 
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with serum indium concentrations of 22 to 127 μg/l (3). It is possible that, compared with 
changes in spirometric parameters and serum biomarkers, changes in diffusing capacity 
occur with higher exposure or later in the course of disease. The lack of contemporary 
population-based reference equations may also have contributed. We used reference 
equations developed from a representative sample of an industrial state, but those equations 
are more than 30 years old and were based on analyses that included only white adults and 
relatively few nonsmokers (18). Thus, comparing our measurements to the predicted values 
may have introduced some bias.
Two thirds of the previously studied production workers (7) were no longer employed at the 
facility, and their exclusion from this study may have obscured (for HRCT and diffusing 
capacity) or altered (for spirometry and serum biomarkers) relationships between plasma 
indium concentration and adverse health outcomes variables. Current workers with longer 
tenure and higher plasma indium concentrations may comprise a “survivor” group that is 
healthier than the initial cohort. There is evidence from the spline regressions (Figure 1) of 
such a survival effect (26). For FEV1% and FVC%, there is a nadir in the difference from 
the reference at 1.5 μg/l, and the difference is smaller at higher plasma indium 
concentrations. This pattern could be interpreted, erroneously in our opinion, as indicating 
that a higher indium exposure is protective. Furthermore, the slope of KL-6 (or SP-D) versus 
plasma indium concentration is steep initially but flattens out at higher plasma indium 
concentrations. Although this pattern could be interpreted as suggesting that a level of 
plasma indium exists above which no further adverse effects occur, a more constant slope 
may have been observed if former workers had been included in the present study. 
Nonetheless, our findings remain robust even if a survival effect led us to underestimate 
health effects of exposure to indium compounds.
A previous evaluation (7) and air sampling conducted at the time of this study indicate that 
exposures in this facility exceeded the Japanese standard for respirable indium of 0.0003 
mg/m3 throughout the facility and exceeded the NIOSH-recommended exposure limit for 
total indium of 0.1 mg/m3 in most production areas. Little is known about the relationship 
between airborne levels of indium and plasma indium concentration. Our observation that 
participants with longer tenure had higher mean plasma indium concentration is consistent 
with the conceptualization of plasma indium as a metric of cumulative exposure. One study 
examined workers exposed to indium oxide, indium hydroxide, and indium chloride at an 
indium ingot production facility. Plasma and urine indium concentrations were stable over 
the workweek, and there were no correlations between measured air and plasma or urine 
indium concentrations (27). Nakano and colleagues showed that mean serum indium 
concentration was comparable (8.4 vs. 9.6 μg/l) between current workers and former 
workers whose indium exposure ended an average of nearly 5 years before the study (5). 
Although information on the former workers' earlier serum indium levels was lacking, this 
observation is consistent with accumulation of a lung burden of indium and slow clearance 
from the body. Indeed, in hamsters exposed to indium–tin oxide or indium oxide by 
intratracheal instillation, serum indium concentration increased consistently during the 
follow-up period, up to 78 weeks after the final exposure (28).
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In this indium–tin oxide workforce with short tenure, low median plasma indium 
concentration, and few abnormalities on HRCT, we found consistent associations between 
plasma indium concentration and adverse respiratory health effects. These differences were 
not explained by age, smoking status, tenure, or previous occupational exposure and were 
observed at lower plasma indium concentrations than previously reported. Until more is 
known about long-term outcomes, ongoing medical surveillance of workers and preventive 
efforts aimed at lowering exposures are prudent.
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Restricted cubic splines show the relationship between percent predicted FEV1, percent 
predicted FVC, Krebs von den Lungen (KL)-6, surfactant protein (SP)-D (vertical axis), and 
plasma indium (horizontal axis), adjusted for smoking status (current/former/never) and 
facility tenure (years). Splines for KL-6 and SP-D are also adjusted for age (years). The 
splines model the estimated difference in the value of the health outcome compared with a 
referent (value in the health outcome for plasma indium concentration of 0.015 μg/l, which 
is half of the limit of detection). CL = confidence limit; Obs = observation.
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Table 1
Demographic and employment data of the participating indium–tin oxide facility 
employees*
All Participants Plasma Indium < 1 μg/l Plasma Indium ≥ 1 μg/l P Value†
Number 87 40 40
Age, yr (range) 44 (35–52)‡ 43 (33–50) 47 (40–52) ns
Male 75 (86) 31 (78) 37 (93) 0.055
Race ns
 White 63 (72) 31 (78) 27 (68)
 Asian 9 (10) 4 (10) 5 (13)
 Black 3 (3) 0 2 (5)
 Other/unknown 12 (14) 5 (13) 6 (15)
 Hispanic 8 (9) 3 (8) 4 (10) ns
Smoking status 0.088
 Current 22 (25) 12 (30) 8 (20)
 Former 20 (23) 5 (13) 13 (33)
 Never 45 (52) 23 (58) 19 (48)
 Tenure, yr§ 2 (1.3–5.0) 1.3 (1.0–2.0) 2.8 (1.9–8.2) <0.0001
Job category 0.007
 Production 44 (51) 15 (38) 27 (68)
 Production support 23 (26) 10 (25) 9 (23)
 Laboratory 8 (9) 5 (13) 3 (8)
 Office 12 (14) 10 (25) 1 (3)
Past work with asbestos, silica, or other lung hazards 53 (61) 24 (60) 25 (63) ns
Definition of abbreviation: ns = nonsignificant.
*
Eighty seven (93%) of 94 individuals employed at the facility participated in the study.
†
P values are based on comparison of the two subgroups defined by plasma indium concentration (<1 and ≥1 μg/l) using χ2 test or Fisher's exact 
test for categorical variables and the Mann-Whitney U test for continuous variables. P ≤ 0.05 was considered significant; P values ≤ 0.10 are 
presented.
‡
Data are presented as median (interquartile range) or n (%).
§
Tenure as a facility employee was calculated from self-reported hire date.
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Table 2
Clinical characteristics, pulmonary function, and serum biomarkers of the participating 
indium–tin oxide facility employees
Subject Characteristics All Participants Plasma Indium < 1 μg/l Plasma Indium ≥ 1 μg/l P Value*
Symptom or diagnosis (n = 87) (n = 40) (n = 40)
 Asymptomatic 49 (56)† 25 (63) 20 (50) ns
 Cough 14 (16) 7 (18) 7 (18) ns
 Chronic cough‡ 9 (10) 4 (10) 5 (13) ns
 Sputum production 10 (11) 4 (10) 6 (15) ns
 Chronic sputum production‡ 4 (5) 3 (8) 1 (3) ns
 Dyspnea 14 (16) 3 (8) 10 (25) 0.030
 Wheeze§ 19 (22) 7 (18) 10 (25) ns
 Wheeze without URI§ 5 (6) 0 5 (13) 0.055
 Chest tightness§ 10 (11) 7 (18) 3 (8) ns
Asthma (self-reported)
 Past or current 19 (22) 5 (13) 12 (30) 0.053
 Current 9 (10) 2 (5) 6 (15) ns
Spirometry (n = 75) (n = 37) (n = 37)
 FEV1% predicted (mean ± SEM) 96 ± 1.7 102 ± 1.9 92 ± 2.6 0.002
 FVC % predicted (mean ± SEM) 99 ± 1.6 103 ± 1.9 95 ± 2.3 0.012
 FEV1/FVC % 79 (73–85) 79 (74–85) 81 (68–85) ns
 Obstructive pattern‖ 3 (4) 0 3 (8) ns
 Restrictive pattern¶ 8 (11) 2 (5) 5 (14) ns
 Mixed pattern** 1 (1) 0 1 (3) ns
 Any abnormality†† 12 (16) 2 (5) 9 (24) 0.018
Diffusing capacity‡‡ (n = 74) (n = 36) (n = 37)
DLCO % predicted (mean ± SEM) 91 ± 1.7 94 ± 2.3 89 ± 2.6 ns
VA % predicted (mean ± SEM) 91 ± 1.4 94 ± 1.9 89 ± 1.9 0.056
Low DLCO 8 (11) 2 (6) 6 (16) ns
Low VA 9 (12) 3 (8) 6 (16) ns
Serum biomarker (n = 80) (n = 40) (n = 40)
 CRP, mg/l 0.9 (0.5–2.2) 0.9 (0.5–2.5) 0.7 (0.5–1.8) ns
 LDH, IU/ml 53 (47–60) 52 (48–58) 54 (46–61) ns
 YKL-40, ng/ml 62 (40–96) 63 (40–100) 59 (37–92) ns
 KL-6, U/ml 542 (372–730) 433 (334–560) 649 (469–984) <0.0001
 SP-D, ng/ml 163 (113–233) 147 (94–216) 187 (146–302) 0.027
 GM-CSF autoantibodies, μg/ml 0.5 (0.3–0.7) 0.5 (0.4–0.7) 0.4 (0.3–0.6) 0.075
Definition of abbreviations: CRP = C-reactive protein; DLCO = diffusing capacity of the lungs for carbon monoxide; GM-CSF = granulocyt factor; 
KL = Krebs von den Lungen; LDH = lactate dehydrogenase; ns = nonsignificant; SP-D = surfactant protein-D; URI = upper respiratory infection; 
VA = alveolar volume.
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*
P values are based on comparison of the two subgroups defined by plasma indium (<1 and ≥1 μg/l) using χ2 test or Fisher's exact test for 
categorical variables. For continuous variables, Student's t test was used for normally distributed data and the Mann Whitney U test for 
nonnormally distributed data. P ≤ 0.05 was considered significant; P values ≤ 0.10 are presented.
†
Data are presented as median (interquartile range) or n (%) unless otherwise noted.
‡
Chronic symptoms defined as occurring most days for ≤3 consecutive mo/yr.
§
Any occurrence in the 12 mo preceding evaluation in this study.
‖
Defined as FEV1/FVC and FEV1 below their respective lower limits of normal (fifth percentiles) and FVC above the lower limit of normal (fifth 
percentile).
¶
Defined as FVC below the lower limit of normal (fifth percentile) and FEV1/FVC above the lower limit of normal (fifth percentile).
**
Defined as FEV1/FVC and FVC below their respective lower limits of normal (fifth percentiles).
††
Defined as having obstructive, restrictive, or mixed pattern.
‡‡
Test results for one participant were excluded because they were inadequate.
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Table 3
Plasma indium concentrations of the participating indium–tin oxide facility employees*
Group Number Plasma Indium (μg/l) P Value†
All participants 80 1.0 (0.2–2.3)‡
Tenure§ <0.0001
 ≤2 yr 40 0.4 (0.1–1.1)
 >2 yr 40 1.6 (0.9–5.5)
Job category‖ <0.0001
 Production 42 1.6 (0.8–3.3)
 Production support 19 0.8 (0.2–1.4)
 Laboratory 8 0.6 (0.2–1.8)
 Office 11 0.03 (<0.03–0.3)
*
Eighty (85%) of 94 individuals employed at the facility had plasma indium concentration measured.
†
P values are based on comparisons within groups (tenure or job category) using the Mann-Whitney U test. P ≤ 0.05 was considered significant.
‡
Data are presented as median (interquartile range).
§
Tenure as a facility employee was calculated from self-reported hire date.
‖
Participants in production jobs spent most of their time in production areas where indium compounds were handled in large quantities. Participants 
in production support jobs spent some of their time in production areas. Participants in laboratory jobs spent most of their time in the quality 
control laboratory where indium compounds were handled in smaller quantities. Participants in office jobs spent most of their time in 
administrative or other nonproduction areas where indium compounds were not handled.
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Table 4
Difference from reference values for pulmonary function parameters and serum 
biomarkers by plasma indium concentration*
Plasma Indium†
Difference (95% CI)‡
FEV1, % FVC, % KL-6 (U/ml) SP-D (ng/ml)
0.5 μg/l 0.3 (−10 to 11) 1.2 (−9.3 to 12) 158 (−123 to 439) 50 (−52 to 153)
1.0 μg/l −12 (−21 to −3.9) −7.9 (−16 to 0.7) 143 (−83 to 369) 19 (−64 to 101)
1.5 μg/l −17 (−25 to −8.4) −11 (−19 to −2.8) 232 (17 to 447) 12 (−67 to 90)
2.0 μg/l −14 (−22 to −6.3) −9.5 (−17 to −1.6) 395 (189 to 601) 30 (−45 to 105)
3.0 μg/l −9 (−18 to −0.6) −6.3 (−15 to 2.4) 658 (427 to 888) 63 (−20 to 147)
5.0 μg/l −4.5 (−15 to 6.0) −3.7 (−14 to 6.8) 920 (638 to 1,202) 101 (−2.3 to 204)
7.0 μg/l −3.9 (−14 to 6.6) −4.2 (−15 to 6.4) 976 (692 to 1,259) 115 (11 to 218)
9.0 μg/l −4.2 (−14 to 6.0) −5.4 (−16 − 4.9) 982 (707 to 1,258) 123 (23 to 224)
Definition of abbreviations: CI = confidence interval; KL = Krebs von den Lungen; SP-D = surfactant protein-D.
*
Pulmonary function data are for 74 (85%), and serum biomarker data are for 80 (92%) of 87 participants in this study.
†
The reference group comprised the 4 (5%) participants with assigned plasma indium concentration of 0.015 μg/l (half of the limit of detection).
‡
Differences were calculated using restricted cubic spline regression. Differences with 95% CIs that exclude 0 are in bold.
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Table 5
Linear regression models of log-transformed plasma indium concentration and health 
outcome variables*
Dependent Health Outcome Variable Covariate(s)† Coefficient (β) P Value‡
FEV1% None −2.31 0.015
FEV1% Smoking status, tenure −2.14 0.025
FVC% None −2.00 0.021
FVC% Smoking status, tenure −2.10 0.022
KL-6, U/ml None 133 <0.0001
KL-6, U/ml Smoking status, tenure, age 146 <0.0001
SP-D, ng/ml None 23.8 0.007
SP-D, ng/ml Smoking status, tenure, age 17.9 0.040
Definition of abbreviations: KL = Krebs von den Lungen; SP-D = surfactant protein-D.
*
Pulmonary function data are for 74 (85%) and serum biomarker data are for 80 (92%) of 87 participants in this study.
†
Smoking status was defined as current/former/never; facility tenure and age were in years.
‡
P value is based on test.
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